B. Riley Lowers Harrow (NASDAQ:HROW) Price Target to $65.00

Harrow (NASDAQ:HROW) had its target price dropped by analysts at B. Riley from $69.00 to $65.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. B. Riley’s target price would indicate a potential upside of 149.52% from the stock’s previous close. B. Riley also issued estimates for Harrow’s Q2 2025 earnings at $0.17 EPS, Q3 2025 earnings at $0.21 EPS and Q4 2025 earnings at $0.38 EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $57.00 price objective on shares of Harrow in a report on Monday.

Harrow Stock Performance

Shares of HROW stock opened at $26.05 on Tuesday. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. The business has a fifty day moving average of $28.36 and a 200 day moving average of $37.63. The firm has a market capitalization of $927.77 million, a price-to-earnings ratio of -27.71 and a beta of 0.69. Harrow has a 1 year low of $9.86 and a 1 year high of $59.23.

Harrow (NASDAQ:HROW) last released its earnings results on Thursday, March 27th. The company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.14. The firm had revenue of $66.83 million during the quarter, compared to the consensus estimate of $66.01 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. As a group, research analysts expect that Harrow will post -0.53 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Intech Investment Management LLC purchased a new position in shares of Harrow in the 3rd quarter valued at about $460,000. Charles Schwab Investment Management Inc. grew its holdings in Harrow by 195.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company’s stock valued at $11,313,000 after purchasing an additional 166,602 shares during the period. Quantbot Technologies LP purchased a new stake in shares of Harrow in the third quarter valued at approximately $549,000. FMR LLC raised its stake in shares of Harrow by 521.6% during the 3rd quarter. FMR LLC now owns 11,034 shares of the company’s stock worth $496,000 after buying an additional 9,259 shares during the period. Finally, BNP Paribas Financial Markets lifted its position in shares of Harrow by 3,015.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 79,974 shares of the company’s stock valued at $3,596,000 after buying an additional 77,407 shares in the last quarter. 72.76% of the stock is owned by institutional investors and hedge funds.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.